Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, collagen protein, biotin, and teas in the wellness category; moisturizer, fragrances, face wash, and anti-wrinkle creams in the skincare category; condoms and lubricants in the sexual health category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. It also offers medical consultation services; and engages in the wholesale of non-prescription product sales to retailers. Hims & Hers Health, Inc. is based in San Francisco, California.
IPO Year: 2019
Exchange: NYSE
Website: forhims.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/22/2024 | $24.00 | Buy | Needham |
8/9/2024 | Outperform → In-line | Imperial Capital | |
5/22/2024 | $16.00 → $20.00 | Buy → Neutral | Citigroup |
4/16/2024 | $17.00 → $15.00 | Buy → Hold | Jefferies |
4/10/2024 | $20.00 | Buy | Canaccord Genuity |
2/28/2024 | $16.00 | In-line → Outperform | Imperial Capital |
2/26/2024 | $10.00 | Market Perform | Leerink Partners |
12/7/2023 | $9.00 | In-line | Imperial Capital |
7/28/2023 | $11.00 | Outperform | TD Cowen |
4/11/2023 | $10.00 | Neutral | Robert W. Baird |
Revenue of $315.6 million, up 52% year-over-year in Q2 2024 Net income of $13.3 million; Adjusted EBITDA of $39.3 million in Q2 2024 Subscribers grew to 1.9 million, up 43% year-over-year in Q2 2024 Raises full year 2024 revenue guidance to a range of $1.37 billion to $1.40 billion and Adjusted EBITDA guidance to a range of $140 million to $155 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2024 in a shareholder letter that is posted at investors.hims.com. "Our second quarter results mark an acceleration in what was already an incredibl
Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help the company increase access to health and wellness solutions Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Kåre Schultz to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722754740/en/Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help the company increase access to health and wellness solutions. (Pho
Hims & Hers Health, Inc. ("Hims & Hers") (NYSE:HIMS), the leading health and wellness platform, today announced that it will report second quarter financial results after the market closes on Monday, August 5, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's management tea
Hims & Hers unlocks access to injectable GLP-1 medications, expanding its holistic weight loss program focused on personalized and affordable solutions; prices start as low as $199 a month Hims & Hers Health, Inc., the leading health and wellness platform, today announced the addition of GLP-1 injections to its comprehensive weight loss portfolio, giving customers an affordable way to consistently access safe, high-quality weight loss treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240520817107/en/Hims & Hers unlocks access to injectable GLP-1 medications, expanding its holistic weight loss program focused on persona
Manuel joins Hims & Hers board of directors to help the company further innovate and increase access to healthcare for millions within the personalized health and wellness space Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Anja Manuel to the company's Board of Directors. Ms. Manuel is a co-founder and principal in Rice, Hadley, Gates & Manuel LLC, a strategic consulting firm founded in 2009 that helps U.S. companies navigate international markets and regulatory issues, and a former U.S. government official. This press release features multimedia. View the full release here: https://www.businesswire.com
Revenue of $278.2 million, up 46% year-over-year in 2024 Net income of $11.1 million; Adjusted EBITDA of $32.3 million in Q1 2024 Subscribers grew to 1.7 million, up 41% year-over-year in Q1 2024 Raises full year 2024 guidance to a range of $1.20 billion to $1.23 billion and Adjusted EBITDA to a range of $120 million to $135 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2024 in a shareholder letter that is posted at investors.hims.com. "We are pleased to begin the year with exceptional results and strong momentum throughout the busines
Hims & Hers Health, Inc. ((", Hims &, Hers, ", NYSE:HIMS), the leading health and wellness platform, today announced that it will report first quarter 2024 financial results after the market closes on Monday, May 6, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a mission
Payne joins Hims & Hers board of directors to help the company further build on its leadership position within the personalized health and wellness space Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Christopher Payne to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403772620/en/Payne joins Hims & Hers board of directors to help the company further build on its leadership position within the personalized health and wellness space. (Photo: Business Wire) "Christopher brings extensive experience working dir
Hims & Hers Health, Inc. ((", Hims &, Hers", , NYSE:HIMS), the leading health and wellness platform, today announced that members of the company's management team will be participating in Canaccord Genuity's Virtual eCommerce Sustainable Advantage Forum on March 14, 2024. All events will be webcast live and archived on the Hims & Hers investor relations website at https://investors.forhims.com. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing
Revenue of $872.0 million, up 65% year-over-year in 2023 Net income of $1.2 million; Adjusted EBITDA profitability of $20.6 million in Q4 2023 Subscribers grew to 1.5 million, up 48% year-over-year in Q4 2023 Provides Q1 and full year 2024 guidance, with full year 2024 revenue in the range of $1.17 billion to $1.20 billion and Adjusted EBITDA in the range of $100 million to $120 million Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2023 in a shareholder letter that is posted at investors.hims.com. "Our outstanding results in 2
Needham initiated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $24.00
Imperial Capital downgraded Hims & Hers Health from Outperform to In-line
Citigroup downgraded Hims & Hers Health from Buy to Neutral and set a new price target of $20.00 from $16.00 previously
Jefferies downgraded Hims & Hers Health from Buy to Hold and set a new price target of $15.00 from $17.00 previously
Canaccord Genuity initiated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $20.00
Imperial Capital upgraded Hims & Hers Health from In-line to Outperform and set a new price target of $16.00
Leerink Partners initiated coverage of Hims & Hers Health with a rating of Market Perform and set a new price target of $10.00
Imperial Capital initiated coverage of Hims & Hers Health with a rating of In-line and set a new price target of $9.00
TD Cowen initiated coverage of Hims & Hers Health with a rating of Outperform and set a new price target of $11.00
Robert W. Baird initiated coverage of Hims & Hers Health with a rating of Neutral and set a new price target of $10.00
8-K - Hims & Hers Health, Inc. (0001773751) (Filer)
424B7 - Hims & Hers Health, Inc. (0001773751) (Filer)
S-3ASR - Hims & Hers Health, Inc. (0001773751) (Filer)
10-Q - Hims & Hers Health, Inc. (0001773751) (Filer)
8-K - Hims & Hers Health, Inc. (0001773751) (Filer)
8-K - Hims & Hers Health, Inc. (0001773751) (Filer)
8-K - Hims & Hers Health, Inc. (0001773751) (Filer)
8-K/A - Hims & Hers Health, Inc. (0001773751) (Filer)
144 - Hims & Hers Health, Inc. (0001773751) (Subject)
10-Q - Hims & Hers Health, Inc. (0001773751) (Filer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
Revenue of $315.6 million, up 52% year-over-year in Q2 2024 Net income of $13.3 million; Adjusted EBITDA of $39.3 million in Q2 2024 Subscribers grew to 1.9 million, up 43% year-over-year in Q2 2024 Raises full year 2024 revenue guidance to a range of $1.37 billion to $1.40 billion and Adjusted EBITDA guidance to a range of $140 million to $155 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2024 in a shareholder letter that is posted at investors.hims.com. "Our second quarter results mark an acceleration in what was already an incredibl
Hims & Hers Health, Inc. ("Hims & Hers") (NYSE:HIMS), the leading health and wellness platform, today announced that it will report second quarter financial results after the market closes on Monday, August 5, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's management tea
Revenue of $278.2 million, up 46% year-over-year in 2024 Net income of $11.1 million; Adjusted EBITDA of $32.3 million in Q1 2024 Subscribers grew to 1.7 million, up 41% year-over-year in Q1 2024 Raises full year 2024 guidance to a range of $1.20 billion to $1.23 billion and Adjusted EBITDA to a range of $120 million to $135 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2024 in a shareholder letter that is posted at investors.hims.com. "We are pleased to begin the year with exceptional results and strong momentum throughout the busines
Hims & Hers Health, Inc. ((", Hims &, Hers, ", NYSE:HIMS), the leading health and wellness platform, today announced that it will report first quarter 2024 financial results after the market closes on Monday, May 6, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a mission
Revenue of $872.0 million, up 65% year-over-year in 2023 Net income of $1.2 million; Adjusted EBITDA profitability of $20.6 million in Q4 2023 Subscribers grew to 1.5 million, up 48% year-over-year in Q4 2023 Provides Q1 and full year 2024 guidance, with full year 2024 revenue in the range of $1.17 billion to $1.20 billion and Adjusted EBITDA in the range of $100 million to $120 million Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2023 in a shareholder letter that is posted at investors.hims.com. "Our outstanding results in 2
Hims & Hers Health, Inc. ((", Hims &, Hers", , NYSE:HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2023 financial results after the market closes on Monday, February 26, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of t
Revenue of $226.7 million, up 57% year-over-year in Q3 2023 Net loss of $7.6 million; Adjusted EBITDA profitability of $12.3 million in Q3 2023 Subscribers grew to 1.4 million, up 56% year-over-year in Q3 2023 Exited Q3 2023 with over 80% of orders fulfilled via affiliated facilities Raises full year 2023 revenue guidance to a range of $868 million to $873 million and Adjusted EBITDA guidance to a range of $43 million to $46 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today reported financial results for the third quarter ended September 30, 2023. "I am proud of the progress made across several of our
Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report third quarter 2023 financial results after the market closes on Monday, November 6, 2023. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a missio
Revenue of $207.9 million, up 83% year-over-year in Q2 2023 Net loss of $7.2 million; Adjusted EBITDA profitability of $10.6 million in Q2 2023 Subscribers grew to 1.3 million, up 74% year-over-year in Q2 2023 Raises full year 2023 revenue guidance to a range of $830 million to $850 million and Adjusted EBITDA guidance to a range of $35 million to $40 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today reported financial results for the second quarter ended June 30, 2023. "This quarter marks a significant turning point for Hims & Hers, where step-change progress was made in transforming our company from an
Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report second quarter 2023 financial results after the market closes on Monday, August 7, 2023. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.forhims.com and will be archived for one year. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a miss
Hims & Hers Health, Inc. (NYSE:HIMS) saw a notable surge in its stock Tuesday possibly from continued momentum from yesterday. Here’s what you need to know. What To Know: The company is scheduled to release its second-quarter earnings report on August 5th, after market close. The company's estimated earnings per share (EPS) for the quarter stands at 4 cents, with revenue projections at approximately $299.9 million What Else: In a significant development for the pharmaceutical industry, Novo Nordisk's weight-loss drug Wegovy has received expanded approval in the UK. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has now approved Wegovy not just for obesity treatment b
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Tuesday. Shares of Danaher Corporation (NYSE:DHR) rose sharply during Tuesday's session after the company reported better-than-expected second quarter earnings. Danaher's second quarter sales decreased 3% year-over-year to $5.743 billion, beating the consensus of $5.59 billion. Danaher reported second-quarter adjusted EPS of $1.72, beating the consensus of $1.57, according to data from Benzinga Pro. Danaher shares gained 7.4% to $269.35 on Tuesday. Here are some other big stocks recording gains in today’s session. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) shares jumped 16% to $24.81 af
- Bloomberg
Hims & Hers Health Inc. (NYSE:HIMS) shares are moving higher on Monday after the company appointed former Novo Nordisk COO and President Kåre Schultz‘s to its Board of Directors. Schultz brings extensive experience from his leadership roles at Novo Nordisk Inc. (NYSE:NVO), Teva Pharmaceutical Industries LTD (NYSE:TEVA) and Lundbeck. At Novo Nordisk, Schultz was instrumental in establishing the company as a leader in diabetes care. “Kåre’s experience gives us an incredible wealth of expertise as we bring together the most valuable elements of clinical excellence, healthcare and technology to redefine health and wellness for our customers.” said CEO Andrew Dudum. Price Action: H
- Bloomberg
Truist Securities analyst Jailendra Singh maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from $13 to $23.
U.S. stocks were higher, with the Nasdaq Composite index gaining around 100 points on Friday. Shares of The Bank of New York Mellon Corporation (NYSE:BK) rose during Friday's session following better-than-expected quarterly financial results. The finance behemoth reported second-quarter adjusted earnings per share of $1.51, beating the street view of $1.43. Quarterly revenue of $4.597 billion, an increase of 2% year-over-year, surpassed the analyst consensus of $4.523 billion, according to data from Benzinga Pro. Bank of New York Mellon shares surged 4.3% to $64.12 on Friday. Here are some other big stocks recording gains in today’s session. Lucid Group, Inc. (NASDAQ:LCID) sh
SC 13D/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13D/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13D/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help the company increase access to health and wellness solutions Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Kåre Schultz to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722754740/en/Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help the company increase access to health and wellness solutions. (Pho
Manuel joins Hims & Hers board of directors to help the company further innovate and increase access to healthcare for millions within the personalized health and wellness space Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Anja Manuel to the company's Board of Directors. Ms. Manuel is a co-founder and principal in Rice, Hadley, Gates & Manuel LLC, a strategic consulting firm founded in 2009 that helps U.S. companies navigate international markets and regulatory issues, and a former U.S. government official. This press release features multimedia. View the full release here: https://www.businesswire.com
Payne joins Hims & Hers board of directors to help the company further build on its leadership position within the personalized health and wellness space Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Christopher Payne to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403772620/en/Payne joins Hims & Hers board of directors to help the company further build on its leadership position within the personalized health and wellness space. (Photo: Business Wire) "Christopher brings extensive experience working dir
Dr. Daniel Lieberman was previously a Clinical Professor of Psychiatry and Behavioral Sciences at George Washington University Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform on a mission to help the world feel great through the power of better health, today announces a key leadership appointment, naming psychiatry and behavioral sciences industry veteran Dr. Daniel Lieberman, M.D., as the company's Senior Vice President of Mental Health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005429/en/(Photo: Business Wire) In this role, Dr. Lieberman will oversee the psychiatry and
Dr. Scott Knoer was previously Chief Pharmacy Officer at Cleveland Clinic & CEO of the American Pharmacists Association Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the trusted consumer-first platform focused on providing modern personalized health and wellness experiences to consumers, today made a key leadership appointment, naming pharmacy industry veteran Dr. Scott Knoer, Pharm.D., MS, FASHP, as the company's first-ever Chief Pharmacy & Innovation Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221205005225/en/Dr. Scott Knoer, Chief Pharmacy & Innovation Officer at Hims & Hers (Photo: Business Wire) In this
New executives bring experience from Google, Skype, Walmart & Amazon Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the trusted consumer-first platform focused on providing modern personalized health and wellness experiences to consumers, has added two high-profile executives to its leadership ranks as the company continues to deliver improving financial performance, including rapid topline growth and increasing scale. Silicon Valley communications veteran Brian O'Shaughnessy has been appointed the company's first Chief Communications Officer. Josh Krueger has been named VP of Fulfillment Operations, bringing over a decade of experience in fulfillment leadership roles at Walmart an
Parekh brings experience scaling high-growth companies & adds to recent leadership appointments as Hims & Hers continues to post strong growth Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, has appointed Uber veteran Amee Parekh as the company's Senior Vice President of Human Resources. Parekh brings a background helping high-growth companies scale and is the latest leadership appointment as Hims & Hers continues to post rapid growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220301005100/en
Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, today announced a number of leadership appointments that firmly position the company for success in pursuit of its mission to transform the legacy healthcare and wellness industry. The company has named Yemi Okupe – a PayPal, eBay, Google, Braintree, and Uber veteran with a decade of experience scaling high-growth, industry-disrupting companies – as Chief Financial Officer. Additionally, Hims & Hers Chief Medical Officer Dr. Patrick Carroll is being elevated to the company's Board of Directors. This press releas
Jay Spitzer Joins the Company After Over a Decade at Walgreens Boots Alliance Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, has appointed Jay Spitzer, CFA as Senior Vice President of Investor Relations. Spitzer joins Hims & Hers from Walgreens Boots Alliance, Inc. where he spent over a decade in investor relations and financial leadership positions. Most recently, Spitzer served as the Vice President of Investor Relations for WBA. This year, the WBA investor relations team was named one of America's best IR teams by Institutional Investor. Spitzer was als
Smooth six month transition plan in place; The search for Company's next CFO has begun; Company reaffirms Q3 and FY 2021 guidance Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the multi-specialty telehealth platform that provides modern personalized health and wellness experiences to consumers, today announced that Spencer Lee plans to step down from his role as the company's Chief Financial Officer. Lee, who joined the company in March 2019, will lead a six month transition plan and continue to support the company until a new CFO is appointed to ensure a smooth transition. The search for a new Chief Financial Officer has begun and is being led by Co-Founder and CEO Andrew Dudum